% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Dimopoulos:142330,
author = {M. A. Dimopoulos and D. Dytfeld and S. Grosicki and P.
Moreau and N. Takezako and M. Hori and X. Leleu and R.
LeBlanc and K. Suzuki and M.-S. Raab$^*$ and P. G.
Richardson and M. Popa McKiver and Y.-M. Jou and S. G.
Shelat and M. Robbins and B. Rafferty and J. San-Miguel},
title = {{E}lotuzumab plus {P}omalidomide and {D}examethasone for
{M}ultiple {M}yeloma.},
journal = {The New England journal of medicine},
volume = {379},
number = {19},
issn = {1533-4406},
address = {Waltham, Mass.},
publisher = {MMS},
reportid = {DKFZ-2019-00106},
pages = {1811 - 1822},
year = {2018},
abstract = {The immunostimulatory monoclonal antibody elotuzumab plus
lenalidomide and dexamethasone has been shown to be
effective in patients with relapsed or refractory multiple
myeloma. The immunomodulatory agent pomalidomide plus
dexamethasone has been shown to be effective in patients
with multiple myeloma that is refractory to lenalidomide and
a proteasome inhibitor.Patients with multiple myeloma that
was refractory or relapsed and refractory to lenalidomide
and a proteasome inhibitor were randomly assigned to receive
elotuzumab plus pomalidomide and dexamethasone (elotuzumab
group) or pomalidomide and dexamethasone alone (control
group). The primary end point was investigator-assessed
progression-free survival.A total of 117 patients were
randomly assigned to the elotuzumab group (60 patients) or
the control group (57 patients). After a minimum follow-up
period of 9.1 months, the median progression-free survival
was 10.3 months in the elotuzumab group and 4.7 months in
the control group. The hazard ratio for disease progression
or death in the elotuzumab group as compared with the
control group was 0.54 $(95\%$ confidence interval [CI],
0.34 to 0.86; P=0.008). The overall response rate was $53\%$
in the elotuzumab group as compared with $26\%$ in the
control group (odds ratio, 3.25; $95\%$ CI, 1.49 to 7.11).
The most common grade 3 or 4 adverse events were neutropenia
$(13\%$ in the elotuzumab group vs. $27\%$ in the control
group), anemia $(10\%$ vs. $20\%),$ and hyperglycemia $(8\%$
vs. $7\%).$ A total of $65\%$ of the patients in each group
had infections. Infusion reactions occurred in 3 patients
$(5\%)$ in the elotuzumab group.Among patients with multiple
myeloma in whom treatment with lenalidomide and a proteasome
inhibitor had failed, the risk of progression or death was
significantly lower among those who received elotuzumab plus
pomalidomide and dexamethasone than among those who received
pomalidomide plus dexamethasone alone. (Funded by
Bristol-Myers Squibb and AbbVie Biotherapeutics; ELOQUENT-3
ClinicalTrials.gov number, NCT02654132 .).},
keywords = {Antibodies, Monoclonal, Humanized (NLM Chemicals) /
Immunologic Factors (NLM Chemicals) / elotuzumab (NLM
Chemicals) / Thalidomide (NLM Chemicals) / Dexamethasone
(NLM Chemicals) / pomalidomide (NLM Chemicals)},
cin = {G170},
ddc = {610},
cid = {I:(DE-He78)G170-20160331},
pnm = {317 - Translational cancer research (POF3-317)},
pid = {G:(DE-HGF)POF3-317},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:30403938},
doi = {10.1056/NEJMoa1805762},
url = {https://inrepo02.dkfz.de/record/142330},
}